MedPath

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Phase 2
Active, not recruiting
Conditions
Epileptic Encephalopathy
Continuous Spike and Wave During Sleep
Interventions
Drug: NBI-827104
Registration Number
NCT05301894
Lead Sponsor
Neurocrine Biosciences
Brief Summary

The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).

Detailed Description

This study will enroll participants who completed treatment in the Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group Study NBI-827104-CSWS2010 (NCT04625101). Participants who did not participate in Study NBI-827104-CSWS2010 may also be eligible for enrollment.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
24
Inclusion Criteria

For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:

  • Completed 12 weeks of treatment in Study NBI-827104-CSWS2010.

For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:

  • Have diagnosis of EECSWS confirmed by the Diagnosis Confirmation Panel (DCP).

Key

Read More
Exclusion Criteria

For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:

  • Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance.

For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:

  • Body weight <15 kg at Day 1.
  • Clinically relevant findings related to cardiovascular or laboratory parameters at screening as determined by the investigator.
  • Presence of relevant neurological disorders other than EECSWS and its underlying conditions as judged by the investigator. Symptomatic conditions underlying EECSWS (for example, neonatal strokes) have to be stable for at least 1 year prior to screening.
  • Planned surgical intervention related to structural abnormalities of the brain from screening through the Week 6 Visit.
  • Used any active investigational drug other than NBI-827104 in the context of a clinical study within 30 days or 5 half-lives (whichever is longer) before screening or plans to use such an investigational drug (other than NBI-827104) during the study.
  • Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
NBI-827104NBI-827104NBI-827104 administered orally
Primary Outcome Measures
NameTimeMethod
The Occurrence of Serious Treatment-emergent Adverse Events (TEAEs)Day 1 up to 238 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Neurocrine Clinical Site

🇬🇧

London, United Kingdom

Neurocrine Clinical Site
🇬🇧London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath